SCHEMBL6507700

SCHEMBL6507700

O=[N+]([O-])c1cccc(-c2ccc(C=NNc3nc4nonc4nc3Nc3ccc(F)cc3)o2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.52
MEN1 O00255 11/20 0.52
KMT2A Q03164 11/20 0.52
HTT P42858 3/20 0.52
SMN1; SMN2 Q16637 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
BIRC5 O15392 1/20 0.51
MAPK1 P28482 2/20 0.51
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
HPGD P15428 1/20 0.50
ALOX12 P18054 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
KDM4E B2RXH2 2/20 0.49
GAA P10253 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
RAB9A P51151 2/20 0.47
POLB P06746 1/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
SAE1 Q9UBE0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6507696 1.00 MAPT (0.52) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL6436709 0.92 MAPT (0.57) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL6436712 0.92 MAPT (0.57) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL6414077 0.92 MAPT (0.53) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL6414075 0.92 MAPT (0.53) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL6415667 0.90 KMT2A (0.53) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL6415669 0.90 KMT2A (0.53) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL6415154 0.90 MAPT (0.49) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL6415150 0.90 MAPT (0.49) MAPTMEN1KMT2AHTTSMN1; SMN2
SCHEMBL6438174 0.88 MAPT (0.51) MAPTMEN1KMT2AHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885MEN1 4392/4885KMT2A 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.